98%
921
2 minutes
20
The side effects of cancer therapy continue to cause significant health and cost burden to the patient, their friends and family, and governments. A major barrier in the way in which these side effects are managed is the highly siloed mentality that results in a fragmented approach to symptom control. Increasingly, it is appreciated that many symptoms are manifestations of common underlying pathobiology, with changes in the gastrointestinal environment a key driver for many symptom sequelae. Breakdown of the mucosal barrier (mucositis) is a common and early side effect of many anti-cancer agents, known to contribute (in part) to a range of highly burdensome symptoms such as diarrhoea, nausea, vomiting, infection, malnutrition, fatigue, depression, and insomnia. Here, we outline a rationale for how, based on its already documented effects on the gastrointestinal microenvironment, medicinal cannabis could be used to control mucositis and prevent the constellation of symptoms with which it is associated. We will provide a brief update on the current state of evidence on medicinal cannabis in cancer care and outline the potential benefits (and challenges) of using medicinal cannabis during active cancer therapy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10781684 | PMC |
http://dx.doi.org/10.1038/s41416-023-02466-w | DOI Listing |
Psychopharmacology (Berl)
September 2025
Center for Medicinal Cannabis Research, Department of Psychiatry, University of California San Diego, San Diego, CA, USA.
Rationale: Between periods of use, chronic cannabis consumers may display residual effects on selective cognitive functions, particularly memory and attention. Whether there are comparable deficits in real-world behaviors, such as driving, has not been thoroughly examined.
Objectives: The current study explored the association between driving simulator performance, cannabis use history, and demographic factors after ≥ 48 h of abstinence.
Cannabis
July 2025
Institute for Mental Health Policy Research, Centre for Addiction and Mental Health.
Objective: The diversity and potency of cannabis products have increased in recent years, underscoring the importance of understanding which products are being used and why. Patients with substance use disorders (SUDs) use have a high prevalence of risky cannabis use, making it especially important to understand use patterns in this group. We aimed to first describe cannabis product characteristics and then explore reasons for choosing products in our sample.
View Article and Find Full Text PDFCannabis
July 2025
Peter Boris Centre for Addictions Research, McMaster University & St. Joseph's Healthcare Hamilton.
Objective: The Diagnostic and Statistical Manual of Mental Disorders version 5 (DSM-5) defines cannabis use disorder as a polythetic unidimensional diagnosis (>2 symptoms from up to 11), but few studies have empirically evaluated the latent structure of CUD. Rasch analysis is a psychometric technique that has previously been used to validate unidimensional scales, like DSM-5 CUD.
Method: In this study, the Rasch model was used to evaluate the DSM-5 CUD criteria in a clinical sample of adults receiving inpatient treatment for substance use disorder ( = 249) reporting active cannabis use at admission.
J Gen Intern Med
September 2025
Center for Data to Discovery and Delivery Innovation (3DI), San Francisco VA Health Care System, San Francisco, CA, USA.
Background: Cannabis may cause chronic pulmonary disease. Prior studies have been limited by low cannabis exposure, lack of data on tobacco cigarettes, and/or limited numbers of those without tobacco cigarette use.
Objective: To examine whether inhaled cannabis associated with asthma and chronic obstructive pulmonary disease, independent of tobacco cigarettes.
Clin Toxicol (Phila)
September 2025
Ramathibodi Poison Center, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Introduction: Cannabis was a category 5 narcotic in Thailand before legalization for medical use in February 2019. In June 2022, it was removed from the narcotics list.
Objectives: To characterize cannabis cases reported to a poison center in Thailand and to analyze the impact of medical and recreational legalization.